FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Zoledronic Acid (Zometa) Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Novartis (New 10/29/2018)

Company Contact Information:
888-669-6682

Presentation Posting Date Related Information
Zometa (zoledronic acid) VIAL 4mg/5mL 5mL in 1 Vial (NDC 0078-0387-25) 10/29/2018 Novartis Pharmaceuticals has made a business decision to permanently discontinue commercial sale of the product Zometa Vial 4mg/5mL. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns. There are therapeutic equivalents available.
Zometa (zoledronic acid) VIAL 4mg/100mL 100mL in 1 Vial (NDC 0078-0590-61) 10/29/2018 Novartis Pharmaceuticals has made a business decision to permanently discontinue commercial sale of the product Zometa Vial 4mg/100mL. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.There are therapeutic equivalents available.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English